Using NESA to help cancer survivors with treatment side effects
Effectiveness of NESA in the Treatment of Sleep Problems, Fatigue, and Neuromuscular Pain in Cancer Survivors.
This study is testing if a new treatment called NESA can help cancer survivors feel better by reducing pain, fatigue, and sleep problems caused by their previous treatments.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | University of Las Palmas de Gran Canaria Academic / other |
| Locations | 1 site (Santa Maria Del Camí, Balearic) |
| Trial ID | NCT06230679 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of NESA, a non-invasive neuromodulation technique, in treating common long-term side effects experienced by cancer survivors, such as pain, fatigue, and sleep difficulties. Participants will be randomly assigned to either an intervention group receiving electrical stimulation or a sham group without stimulation, ensuring that neither the patients nor the researchers know which group they belong to. The goal is to provide an additional therapeutic tool for healthcare professionals in oncology to improve the quality of life for cancer survivors.
Who should consider this trial
Good fit: Ideal candidates are cancer survivors who have been discharged for at least five years and experience symptoms like sleep problems, chronic fatigue, or chronic pain.
Not a fit: Patients currently undergoing cancer treatment or those with contraindications to the NESA device will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly alleviate the long-term side effects experienced by cancer survivors, enhancing their quality of life.
How similar studies have performed: While the approach of using neuromodulation for symptom management in cancer survivors is promising, it remains relatively novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Be a cancer survivor (5 years after discharge) * Have 1 of the 3 symptoms of the most common cluster: sleep problems, chronic fatigue, chronic neuro-muscular pain. Exclusion Criteria: * Not have an active oncological process * Present any of the contraindications of the NESA-XSignal device: pacemaker, internal bleeding, skin in poor condition (ulcerations or wounds), acute febrile processes, acute thrombophlebitis, pregnancy, phobia of electricity.
Where this trial is running
Santa Maria Del Camí, Balearic
- Gutmotion — Santa Maria Del Camí, Balearic, Spain (Recruiting)
Study contacts
- Principal investigator: Gabriel Amengual Jaume, MSc — University of Las Palmas de Gran Canaria
- Study coordinator: Gabriel Amengual Jaume, MSc
- Email: biel@gutmotion.net
- Phone: +34 971 07 86 67
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.